These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 1643710)
1. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Vanholder RC; De Smet RV; Ringoir SM Clin Chem; 1992 Aug; 38(8 Pt 1):1429-36. PubMed ID: 1643710 [TBL] [Abstract][Full Text] [Related]
2. Are the classical markers sufficient to describe uremic solute accumulation in dialyzed patients? Hippurates reconsidered. Schoots AC; Dijkstra JB; Ringoir SM; Vanholder R; Cramers CA Clin Chem; 1988 Jun; 34(6):1022-9. PubMed ID: 3378319 [TBL] [Abstract][Full Text] [Related]
3. HPLC study of uremic fluids related to optical dialysis adequacy monitoring. Lauri K; Tanner R; Jerotskaja J; Luman M; Fridolin I Int J Artif Organs; 2010 Feb; 33(2):96-104. PubMed ID: 20306436 [TBL] [Abstract][Full Text] [Related]
4. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767 [TBL] [Abstract][Full Text] [Related]
5. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? Eloot S; Van Biesen W; Glorieux G; Neirynck N; Dhondt A; Vanholder R PLoS One; 2013; 8(11):e76838. PubMed ID: 24236005 [TBL] [Abstract][Full Text] [Related]
6. Screening of UV-absorbing solutes in uremic serum by reversed phase HPLC--change of blood levels in different therapies. Schoots AC; Homan HR; Gladdines MM; Cramers CA; de Smet R; Ringoir SM Clin Chim Acta; 1985 Feb; 146(1):37-51. PubMed ID: 3987038 [TBL] [Abstract][Full Text] [Related]
7. Effect of hemodialysis on serum concentrations of HPLC-analyzed accumulating solutes in uremia. Schoots AC; Peeters JA; Gerlag PG Nephron; 1989; 53(3):208-17. PubMed ID: 2507950 [TBL] [Abstract][Full Text] [Related]
8. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. De Smet R; Vogeleere P; Van Kaer J; Lameire N; Vanholder R J Chromatogr A; 1999 Jun; 847(1-2):141-53. PubMed ID: 10431358 [TBL] [Abstract][Full Text] [Related]
9. Ultraviolet-absorbing organic anions in uremic serum separated by capillary zone electrophoresis, and quantification of hippuric acid. Schoots AC; Verheggen TP; De Vries PM; Everaerts FM Clin Chem; 1990 Mar; 36(3):435-40. PubMed ID: 2311210 [TBL] [Abstract][Full Text] [Related]
10. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid. Boumendil-Podevin EF; Podevin RA; Richet G J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164 [TBL] [Abstract][Full Text] [Related]
11. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774 [TBL] [Abstract][Full Text] [Related]
12. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes. Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534 [TBL] [Abstract][Full Text] [Related]
13. Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia. Vanholder R; De Smet R; Schoots A; Ringoir S Nephron; 1988; 49(2):164-8. PubMed ID: 3380232 [TBL] [Abstract][Full Text] [Related]
14. Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Gulyassy PF; Jarrard E; Stanfel LA Biochem Pharmacol; 1987 Dec; 36(24):4215-20. PubMed ID: 3120733 [TBL] [Abstract][Full Text] [Related]
15. Liquid-chromatographic profiling of solutes in serum of uremic patients undergoing hemodialysis and chronic ambulatory peritoneal dialysis (CAPD); high concentrations of pseudouridine in CAPD patients. Schoots AC; Gerlag PG; Mulder AW; Peeters JA; Cramers CA Clin Chem; 1988 Jan; 34(1):91-7. PubMed ID: 3338190 [TBL] [Abstract][Full Text] [Related]
16. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis. Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048 [TBL] [Abstract][Full Text] [Related]
17. Protein-bound uremic solutes: the forgotten toxins. Vanholder R; De Smet R; Lameire N Kidney Int Suppl; 2001 Feb; 78():S266-70. PubMed ID: 11169024 [TBL] [Abstract][Full Text] [Related]
18. Determination of hippuric acid and furanic acid in serum of dialysis patients and control persons by high-performance liquid chromatography. Pickert A; Bäuerle A; Liebich HM J Chromatogr; 1989 Oct; 495():95-104. PubMed ID: 2613830 [TBL] [Abstract][Full Text] [Related]
19. Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis. Farrell PC; Gotch FA; Peters JH; Berridge BJ; Lam M Nephron; 1978; 20(1):40-6. PubMed ID: 619299 [TBL] [Abstract][Full Text] [Related]